CHAC1 antibodies are immunological reagents specifically designed to detect and bind to the CHAC1 protein, a member of the gamma-glutamylcyclotransferase family. These antibodies have become increasingly important in research settings as CHAC1 has been implicated in various cellular processes and pathological conditions, including endoplasmic reticulum stress responses, glutathione metabolism, and cancer progression. CHAC1 antibodies are commercially available in multiple formats from various manufacturers, each optimized for specific experimental applications and research needs .
The significance of CHAC1 antibodies lies in their ability to reliably detect CHAC1 protein expression across different experimental conditions, enabling researchers to investigate the role of this protein in normal cellular function and in disease states. As research tools, these antibodies have contributed significantly to our understanding of CHAC1's biological functions and its involvement in various pathological processes.
Understanding the structure and function of the CHAC1 protein is essential for appreciating the utility and applications of CHAC1 antibodies. CHAC1 is a 24 kDa protein (though often observed at approximately 38 kDa in experimental settings) that functions as a glutathione-specific gamma-glutamylcyclotransferase .
CHAC1 catalyzes the cleavage of glutathione into 5-oxo-L-proline and a Cys-Gly dipeptide, acting specifically on glutathione but not on other gamma-glutamyl peptides . This glutathione-degrading activity is significant because glutathione is the major intracellular antioxidant, making CHAC1 an important regulator of cellular redox balance and oxidative stress responses . The depletion of glutathione is also an important factor in apoptosis initiation and execution, connecting CHAC1 to cell death pathways .
CHAC1 functions as a pro-apoptotic component of the unfolded protein response pathway, mediating the pro-apoptotic effects of the ATF4-ATF3-DDIT3/CHOP cascade . The regulation of CHAC1 expression involves several transcription factors, including ATF4, ATF3, and CCAAT/enhancer-binding protein β (CEBPβ), which bind to specific elements in the CHAC1 promoter region . Recent research has also identified E2F Transcription Factor 1 as a potent activator of CHAC1 transcription in lung adenocarcinoma cells .
Beyond its role in stress responses, CHAC1 acts as a negative regulator of the Notch signaling pathway involved in embryonic neurogenesis. It inhibits Notch cleavage by furin, maintaining Notch in an immature inactive form, thereby promoting neurogenesis in embryos .
CHAC1 antibodies are available in various formats, each with distinct characteristics suitable for different experimental applications. The main types of CHAC1 antibodies can be categorized based on their clonality, host species, and targeted epitopes.
Commercially available CHAC1 antibodies include both monoclonal and polyclonal variants:
Monoclonal CHAC1 antibodies: These antibodies are derived from a single B-cell clone, resulting in antibodies that recognize a single epitope on the CHAC1 protein. Examples include the mouse monoclonal CHAC1 antibody clone OTI1E2, which is suitable for immunohistochemistry on paraffin-embedded tissues (IHC-P) and reacts with human samples .
Polyclonal CHAC1 antibodies: These antibodies are derived from multiple B-cell lineages and recognize multiple epitopes on the CHAC1 protein. Examples include rabbit polyclonal antibodies that are suitable for Western blot (WB), immunohistochemistry (IHC), immunofluorescence (IF), and other applications, with reactivity against human, mouse, rat, and other species .
The majority of commercially available CHAC1 antibodies are rabbit-derived, though mouse monoclonal options are also available . These antibodies target various regions of the CHAC1 protein, including:
CHAC1 antibodies have been utilized in various experimental applications to investigate the expression, localization, and function of CHAC1 protein in different biological contexts.
Western blotting (WB) is one of the most common applications for CHAC1 antibodies, allowing researchers to detect and quantify CHAC1 protein expression in cell and tissue lysates. Most commercial CHAC1 antibodies are validated for WB applications, with recommended dilutions typically ranging from 1:500 to 1:2000 . In WB applications, CHAC1 is typically observed as a band at approximately 38 kDa, despite its calculated molecular weight of 24 kDa .
Immunohistochemistry (IHC) applications of CHAC1 antibodies enable the visualization of CHAC1 protein expression in tissue sections, providing valuable insights into its localization and expression patterns in various physiological and pathological conditions. Several commercial CHAC1 antibodies are validated for IHC applications, with recommended dilutions ranging from 1:50 to 1:500 .
IHC studies using CHAC1 antibodies have revealed important findings, such as the overexpression of CHAC1 in Helicobacter pylori-infected parietal cells in the gastric mucosa . In these studies, CHAC1 antibodies helped identify varying degrees of CHAC1 expression in fundic-gland areas of gastric mucosa, with stronger expression observed in H. pylori-infected tissues .
Immunofluorescence (IF) applications of CHAC1 antibodies allow for the detailed visualization of CHAC1 protein localization within cells. Several commercial CHAC1 antibodies are validated for IF applications . For example, immunofluorescent analysis of CHAC1 in COS7 cells transfected with a plasmid overexpressing CHAC1 has been performed using CHAC1 monoclonal antibodies .
CHAC1 antibodies have also been utilized in other experimental techniques, including:
Immunoprecipitation (IP) and co-immunoprecipitation (CoIP) to study protein-protein interactions involving CHAC1
Enzyme-linked immunosorbent assay (ELISA) for quantitative detection of CHAC1 protein
Chromatin immunoprecipitation (ChIP) assays to investigate transcription factor binding to the CHAC1 promoter region
These diverse applications highlight the versatility of CHAC1 antibodies as research tools for investigating various aspects of CHAC1 biology and function.
Research utilizing CHAC1 antibodies has contributed significantly to our understanding of CHAC1's biological functions and its implications in various disease states.
Studies employing CHAC1 antibodies have revealed that CHAC1 is overexpressed in Helicobacter pylori-infected gastric parietal cells. Immunohistochemistry with anti-CHAC1 monoclonal antibodies showed varying levels of CHAC1 expression in gastric mucosa, with strong expression specifically observed in H. pylori-infected parietal cells . This finding suggests a potential role for CHAC1 in the pathophysiology of H. pylori infection and related gastric disorders.
Recent research has implicated CHAC1 in the progression of lung adenocarcinoma (LUAD). Studies found that CHAC1 expression was markedly higher in LUAD tissues compared to non-tumor tissues and positively correlated with poor prognosis. Mechanistically, CHAC1 was shown to act as a bridge connecting UBA2 and PKM2, enhancing the SUMOylation of PKM2 and subsequently activating the expression of glycolysis-related genes, promoting the Warburg effect in cancer cells . These findings suggest that CHAC1 could be a potential target for cancer therapy, and CHAC1 antibodies may have utility in cancer research and potentially in diagnostic applications.
CHAC1 antibodies have been instrumental in elucidating the role of CHAC1 in cellular stress response pathways. Research has shown that CHAC1 is a downstream target of the ATF4-ATF3-DDIT3/CHOP cascade in the endoplasmic reticulum stress pathway. Chromatin immunoprecipitation (ChIP) studies using antibodies against ATF4, ATF3, and CEBPβ have confirmed the binding of these transcription factors to the CHAC1 promoter region in response to ER stress . These findings highlight the importance of CHAC1 in mediating cellular responses to stress conditions.
Studies utilizing CHAC1 antibodies have confirmed CHAC1's role in glutathione metabolism. Overexpression of CHAC1 in HEK293 cells led to robust depletion of glutathione, which was alleviated in a CHAC1 catalytic mutant . This finding underscores CHAC1's function as a glutathione-degrading enzyme and its potential impact on cellular redox balance and oxidative stress responses.
When working with CHAC1 antibodies, several technical considerations should be taken into account to ensure optimal experimental results.
The optimal dilution for CHAC1 antibodies varies depending on the specific antibody and application. For Western blot applications, recommended dilutions typically range from 1:500 to 1:2000 . For immunohistochemistry, recommended dilutions range from 1:50 to 1:500 . It is advisable to perform optimization experiments to determine the optimal antibody concentration for specific experimental conditions.
For Western blot applications, CHAC1 antibodies have been successfully used with various sample types, including cell lysates from HeLa, A549, CHO, U-251, C6, and RAW 264.7 cells, as well as tissue lysates from mouse brain and kidney . For immunohistochemistry, CHAC1 antibodies have been validated on formalin-fixed, paraffin-embedded human stomach tissue and rat brain tissue .
When using CHAC1 antibodies, it is advisable to include appropriate positive and negative controls to validate antibody specificity and performance. For example, CHAC1-overexpressing cells can serve as positive controls, as demonstrated in immunofluorescence studies with COS7 cells transfected with a CHAC1-overexpressing plasmid .
The development and application of CHAC1 antibodies continue to advance our understanding of CHAC1 biology and its implications in various physiological and pathological processes.
Recent research has uncovered new roles for CHAC1 in various disease states, including cancer, infectious diseases, and stress-related disorders. CHAC1 antibodies will continue to be essential tools for investigating these emerging roles and elucidating the underlying mechanisms. The finding that CHAC1 blockade suppresses the progression of lung adenocarcinoma suggests potential therapeutic applications targeting CHAC1 , which may involve the development of new antibody-based approaches.
As research on CHAC1 continues to expand, there is a growing need for more specific and versatile CHAC1 antibodies. Future developments may include the production of antibodies targeting specific CHAC1 modifications or conformational states, as well as the development of antibodies optimized for emerging experimental techniques. The generation of antibodies against specific CHAC1 functional domains may also provide valuable tools for dissecting CHAC1's various biological activities.
Given CHAC1's involvement in various disease processes, CHAC1 antibodies may have potential diagnostic and therapeutic applications. In cancer diagnostics, CHAC1 antibodies could potentially serve as biomarkers for certain cancer types, such as lung adenocarcinoma, where CHAC1 overexpression correlates with poor prognosis . In therapeutic contexts, antibody-based approaches targeting CHAC1 could potentially modulate its activity in disease states characterized by dysregulated CHAC1 expression or function.
CHAC1 belongs to the chaC family and functions as an enzyme that degrades glutathione. While its complete function remains under investigation, CHAC1 has been identified as a component of the integrated stress response pathway. Research indicates CHAC1 is induced in Helicobacter pylori-infected gastric parietal cells, suggesting its potential role in cellular responses to pathogenic infection . CHAC1 is also implicated in the endoplasmic reticulum (ER) stress response pathway, making it a target of interest for researchers studying cellular stress mechanisms. To effectively study this protein, researchers typically employ anti-CHAC1 antibodies to detect expression patterns across different tissue types and under various experimental conditions.
Various CHAC1 antibodies are available with different specificities and applications. Based on current research resources, these include:
Polyclonal antibodies targeting the C-terminal region of human CHAC1
Antibodies with reactivity to specific amino acid sequences (e.g., AA 43-264, AA 131-222, AA 188-237)
Monoclonal antibodies such as CHAC1-mAb (v1v2) used in immunohistochemistry applications
Conjugated antibodies with tags like HRP, biotin, FITC, and fluorophores for specialized applications
When selecting an antibody, researchers should consider the specific epitope recognition, host species, clonality, and verified applications to ensure compatibility with their experimental design.
Determining the optimal working dilution for CHAC1 antibodies is critically important for experimental success. The appropriate dilution should be determined empirically for each specific application and experimental system . Begin with the manufacturer's recommended range (typically 1:500 to 1:2000 for Western blotting) and perform a dilution series experiment.
For immunohistochemistry applications:
Prepare serial dilutions of the antibody (e.g., 1:100, 1:500, 1:1000, 1:2000)
Apply each dilution to identical tissue sections
Process all sections simultaneously using standard protocols
Evaluate signal-to-noise ratio at each dilution
Select the dilution that provides specific staining with minimal background
For Western blotting, a similar approach should be taken, testing multiple dilutions against the same protein amount. Remember that different lots of the same antibody may require adjusted dilutions, making this optimization process essential for each new antibody lot.
To maintain CHAC1 antibody integrity and functionality, appropriate storage is essential. According to research protocols, CHAC1 antibodies should be stored at -20°C for long-term preservation . For short-term use (up to one week), storage at 2-8°C is acceptable. To prevent protein degradation and activity loss:
Divide the antibody into small aliquots upon receipt to minimize freeze-thaw cycles
Store in recommended buffer conditions (typically PBS with sodium azide and stabilizers)
Avoid repeated freeze-thaw cycles which significantly reduce antibody activity
Follow manufacturer's specific recommendations for each formulation
Document storage conditions and dates when tracking experimental reproducibility
Proper storage significantly impacts experimental reproducibility, especially when working with sensitive applications like immunohistochemistry or immunofluorescence.
CHAC1 antibodies have been validated for several experimental applications, with specific methodological considerations for each:
Western Blotting (WB): CHAC1 antibodies have been validated for detecting the approximately 24 kDa CHAC1 protein . For optimal results:
Use appropriate positive controls (tissues with known CHAC1 expression)
Include reducing agents in sample preparation
Transfer proteins to PVDF or nitrocellulose membranes
Block with 5% skim milk in TBS-T
Incubate with primary antibody overnight at 4°C with shaking
Immunohistochemistry (IHC): For CHAC1 detection in tissue sections:
Perform antigen retrieval using citrate buffer (pH 6.0) for 20 minutes
Block endogenous peroxidase activity with 3% hydrogen peroxide
Use normal horse serum for blocking non-specific binding
Incubate with appropriately diluted primary antibody
Develop using enzyme-conjugated secondary antibodies and appropriate substrates
Immunofluorescence (IF): For cellular localization studies:
Fix cells appropriately (4% paraformaldehyde)
Permeabilize with 0.1% Triton X-100
Block with serum-based blocking buffer
Incubate with primary antibody at optimal dilution
Detect using fluorophore-conjugated secondary antibodies
Validating antibody specificity is crucial for reliable research outcomes. A comprehensive validation approach includes:
Positive and negative controls: Use tissues or cells with known CHAC1 expression levels as positive controls (e.g., stress-induced cells) and those with minimal expression as negative controls
Peptide competition assay: Pre-incubate the antibody with the immunizing peptide before application; specific binding should be blocked
Multiple antibody approach: Compare results using antibodies targeting different epitopes of CHAC1
Genetic validation: Use CHAC1 knockout/knockdown models or overexpression systems to confirm specificity
Western blot analysis: Confirm the antibody detects a single band of expected molecular weight (approximately 24 kDa for CHAC1)
Cross-reactivity assessment: Test against known homologous proteins or across species when working with non-human models
For advanced validation, consider using active site mutants of CHAC1 (e.g., glutamate to glutamine mutations) to confirm specificity for the functional protein versus non-functional variants .
For optimal Western blotting results with CHAC1 antibodies, follow this detailed protocol:
Sample preparation:
Lyse cells in RIPA buffer with protease inhibitors
Quantify protein concentration (Bradford or BCA assay)
Mix samples with Laemmli buffer containing β-mercaptoethanol
Heat at 95°C for 5 minutes
Gel electrophoresis and transfer:
Load 20-40 μg protein per lane on 12-15% SDS-PAGE gels (optimal for 24 kDa CHAC1)
Run at 100-120V until adequate separation
Transfer to PVDF membrane at 100V for 1 hour (wet transfer)
Antibody incubation:
Block with 5% skim milk in TBS-T for 1 hour at room temperature
Incubate with primary CHAC1 antibody (at predetermined optimal dilution) overnight at 4°C with shaking
Wash 3-5 times with TBS-T (5 minutes each)
Incubate with HRP-conjugated secondary antibody for 1 hour at room temperature
Wash 3-5 times with TBS-T (5 minutes each)
Detection:
For enhanced sensitivity when detecting low CHAC1 expression, consider signal amplification systems or more sensitive detection reagents.
CHAC1 is induced as part of the integrated stress response rather than exclusively during ER stress . To effectively study CHAC1 expression dynamics:
Stress induction models:
Time-course experiments:
Collect samples at multiple time points (0, 2, 4, 8, 12, 24 hours)
Analyze CHAC1 protein expression by Western blotting
Compare with known ER stress markers (BiP, CHOP)
Quantification approaches:
Promoter activity analysis:
For optimal CHAC1 detection in tissue samples, implement these specialized IHC techniques:
Tissue preparation:
For FFPE samples: 4% formalin fixation for 24-48 hours followed by paraffin embedding
Section thickness: 4-5 μm for optimal antibody penetration
Mount on positively charged slides
Antigen retrieval (critical step):
Signal enhancement protocol:
Dual-staining protocols for colocalization studies:
For CHAC1 with cell-type markers (e.g., H,K-ATPase for parietal cells)
Use alkaline phosphatase-conjugated secondary antibody with VECTOR Blue Alkaline Phosphatase Substrate Kit III
Alternatively, use fluorescein isothiocyanate-conjugated streptavidin
Between staining rounds, inactivate previous antibodies by microwaving in citrate buffer
Controls and interpretation:
Chromatin immunoprecipitation (ChIP) is valuable for studying transcriptional regulation of CHAC1. Based on research findings that ATF/CRE elements direct CHAC1 transcription, follow this specialized protocol:
Cell preparation:
Crosslinking and chromatin shearing:
Immunoprecipitation:
DNA recovery and analysis:
Release DNA fragments by incubating with 0.2 M NaCl overnight at 65°C
Treat with Proteinase K (0.1 mg/ml)
Purify DNA using a QIAquick PCR purification kit
Analyze by qPCR using primers specific to CHAC1 promoter regions
Validation:
| Issue | Possible Causes | Solutions |
|---|---|---|
| No signal in Western blot | Insufficient protein loading; Antibody concentration too low; Protein degradation | Increase protein loading to 40-60 μg; Optimize antibody dilution; Use fresh samples with protease inhibitors |
| Multiple bands in Western blot | Non-specific binding; Protein degradation; Cross-reactivity | Increase blocking stringency; Use freshly prepared samples; Try different antibody targeting another epitope |
| High background in IHC | Insufficient blocking; Antibody concentration too high; Non-specific binding | Increase blocking time; Optimize antibody dilution; Include additional blocking agents (e.g., BSA) |
| Variable staining intensity in IHC | Inconsistent antigen retrieval; Sample fixation differences; Endogenous peroxidase activity | Standardize antigen retrieval protocol; Control fixation times; Ensure thorough peroxidase blocking |
| Poor reproducibility between experiments | Antibody lot variations; Storage conditions; Protocol inconsistencies | Use same antibody lot; Aliquot antibodies to avoid freeze-thaw cycles; Standardize protocols with detailed SOPs |
Detecting CHAC1 in cells with low baseline expression requires specialized approaches:
Signal amplification strategies:
Use high-sensitivity detection systems (Super Signal West Femto or similar)
Consider biotin-streptavidin amplification systems
For IHC, implement tyramide signal amplification (TSA)
Enrichment approaches:
Concentrate protein samples using immunoprecipitation before Western blotting
For tissue sections, consider thicker sections (6-8 μm) to increase target protein amount
Stress induction:
Technical optimization:
Extend primary antibody incubation time (overnight at 4°C or longer)
Increase antibody concentration while controlling for background
Use highly sensitive digital imaging systems with extended exposure capabilities
Alternative detection methods:
A comprehensive control strategy ensures reliable CHAC1 research findings:
Positive controls:
Negative controls:
Antibody diluent without primary antibody
Isotype control antibodies
Non-stressed cells with minimal CHAC1 expression
Pre-immune serum for polyclonal antibodies
Specificity controls:
Processing controls:
Cross-validation approach:
Confirm findings using multiple antibodies targeting different epitopes
Validate protein expression with corresponding mRNA levels
Use multiple detection techniques (WB, IHC, IF) for comprehensive verification
CHAC1 antibodies have provided valuable insights into H. pylori infection mechanisms:
Cellular tropism studies:
CHAC1 antibodies have revealed that H. pylori specifically induces CHAC1 overexpression in gastric parietal cells that express the proton pump/H,K-ATPase α subunit
Double-enzyme or fluorescence IHC with combinations of anti-H. pylori, anti-proton pump, and anti-CHAC1 antibodies have demonstrated direct infection of parietal cells
Infection-induced molecular changes:
Quantitative analysis of infection impact:
Pathogenesis mechanisms:
Studying CHAC1 promoter regulation requires specialized antibody-based approaches:
ChIP-seq analysis:
Transcription factor binding analysis:
Combine ChIP with qPCR to quantify binding at specific CHAC1 promoter regions
Focus on the region between -267 to +133 relative to transcription start, which is critical for basal and stress-induced transcription
Assess binding enrichment under different stress conditions (ER stress, amino acid starvation)
Reporter assays with antibody validation:
Use CHAC1 promoter-luciferase constructs to assess activity
Combine with siRNA knockdown of transcription factors
Validate knockdown efficiency using antibodies against target transcription factors
Protein-DNA interaction mapping:
Perform DNA affinity precipitation assays using biotinylated CHAC1 promoter fragments
Identify bound proteins using specific antibodies
Confirm interactions using electrophoretic mobility shift assays (EMSA)